Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770114 | 0.83 | GSK3B (0.48) | GSK3BALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL14992457 | 0.81 | CYP3A4 (0.50) | GSK3BALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL9720561 | 0.81 | CYP3A4 (0.47) | ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL14992135 | 0.79 | GSK3B (0.41) | GSK3BALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL3319164 | 0.78 | GSK3B (0.48) | GSK3BALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL21484772 | 0.78 | RAB9A (0.41) | GSK3BALDH1A1MAPTPOLBPTPN1 | |
| SCHEMBL23364578 | 0.76 | GSK3B (0.52) | GSK3BMAPTSMN1; SMN2PTPN1LMNA | |
| SCHEMBL2381417 | 0.76 | GSK3B (0.52) | GSK3BALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL14993161 | 0.76 | GSK3B (0.38) | GSK3BALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL2381033 | 0.76 | GSK3B (0.38) | GSK3BALDH1A1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION | 2021-07-27 | — | — | US | disclosed |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2020-03-17 | — | — | US | disclosed |
| EP-2785714-B1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2018-11-21 | — | — | EP | disclosed |
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | DEVELOPMENT CENTER OF BIOTECHNOLOGY (TW) | 2018-11-08 | — | — | US | disclosed |
| US-9409902-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2016-08-09 | — | — | US | disclosed |
| US-9409902-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2016-08-09 | — | — | US | disclosed |
| US-9409902-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2016-08-09 | — | — | US | disclosed |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2015-09-10 | — | — | US | disclosed |
| EP-2547676-B1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC (TW) | 2015-07-29 | — | — | EP | disclosed |
| EP-2547676-B1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC (TW) | 2015-07-29 | — | — | EP | disclosed |
| US-8946268-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS, INC. (TW) | 2015-02-03 | — | — | US | disclosed |
| EP-2785714-A1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | Taivex Therapeutics Corporation (TW) | 2014-10-08 | — | — | EP | disclosed |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-07-25 | — | — | US | disclosed |
| WO-2013082324-A1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-06-06 | — | — | WO | disclosed |
| EP-2547676-A2 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | Taivex Therapeutics Inc. (TW) | 2013-01-23 | — | — | EP | disclosed |
| US-20110230486-A1 | Modulators Of HEC1 Activity And Methods Therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2011-09-22 | — | — | US | disclosed |
| US-20110230486-A1 | Modulators Of HEC1 Activity And Methods Therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2011-09-22 | — | — | US | disclosed |
| US-20110230486-A1 | Modulators Of HEC1 Activity And Methods Therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2011-09-22 | — | — | US | disclosed |
| WO-2011115998-A2 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC. (CN) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011115998-A2 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC. (CN) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | GSK3B 1041/4885ALDH1A1 3121/4885MEN1 2018/4885 |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | GSK3B 1041/4885ALDH1A1 3121/4885MEN1 2018/4885 |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | GSK3B 1041/4885ALDH1A1 3121/4885MEN1 2018/4885 |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | GSK3B 1041/4885ALDH1A1 3121/4885MEN1 2018/4885 |
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | GSK3B 1041/4885ALDH1A1 3121/4885MEN1 2018/4885 |
| US-20110230486-A1 | Modulators Of HEC1 Activity And Methods Therefor | WEE1, WEE2, NEK11 | GSK3B 1086/4885ALDH1A1 3229/4885MEN1 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.